Breaking News

Tweet TWEET

Biotech Companies Announce Financial Results and Receive New Patents - Research Report on Regeneron, Medivation, Incyte,

    Biotech Companies Announce Financial Results and Receive New Patents -
    Research Report on Regeneron, Medivation, Incyte, Santarus, and ACADIA

PR Newswire

NEW YORK, August 21, 2013

NEW YORK, August 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Medivation, Inc. (NASDAQ:
MDVN), Incyte Corporation (NASDAQ: INCY), Santarus, Inc. (NASDAQ: SNTS), and
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Regeneron Pharmaceuticals, Inc. Research Report

On August 7, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that
it has been granted US Patent No. 8,502,018 by the US Patent and Trademark
Office related to methods of genetically modifying a mouse to make human
antibodies. Regeneron reported that the patent is similar to European patent,
EP 1 360 287 B1, which was granted on September 12, 2012 by the European
Patent Office. These patents are part of Regeneron's global patent portfolio,
which together protect fundamental inventions behind the Company's VelocImmune
humanized mice. George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer
of Regeneron and President of Regeneron Laboratories, and a Co-inventor of
these technologies, stated, "VelocImmune provides perhaps the most powerful
and efficient way of generating fully human monoclonal antibodies that are
ready for clinical testing. Its invention has allowed Regeneron to become a
leading antibody therapeutics company, with twelve clinical stage antibodies
generated through our VelocImmune platform currently in clinical development."
The Full Research Report on Regeneron Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-14/REGN]

Medivation, Inc. Research Report

On August 8, 2013, Medivation, Inc. (Medivation) released its Q2 2013
financial results. Collaboration revenues were up 63.5% YoY to $70.1 million
during the quarter. Income from operations stood at $54,000 in Q2 2013,
compared to a loss of $975,000 in Q2 2012. Net loss was $4.9 million, or $0.07
per diluted share, in Q2 2013, compared to a loss of $5.5 million, or $0.08
per diluted share, in Q2 2012. Medivation expects full-year 2013 US net sales
of XTANDI to be between $345 million and $365 million, as reported by
Astellas. Further, Medivation expects total operating expenses, net of
cost-sharing payments from Astellas, to be between $285 million and $300
million. The Full Research Report on Medivation, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-14/MDVN]

Incyte Corporation Research Report

On August 1, 2013, Incyte Corporation (Incyte) released its Q2 2013 financial
results. Total revenues were up 17.5% YoY to $101.7 million, while income from
operations grew 13.8% YoY to $17.3 million during the quarter. Net loss stood
at $2.6 million, or $0.02 per diluted share, in Q2 2013, compared to net
income of $4.0 million, $0.03 per diluted share, in Q2 2012. Incyte also
raised its full-year Jakafi net product revenue guidance to be in the range of
$220 million to $230 million from previously announced guidance range of $210
million to $225 million. Paul A. Friedman, M.D., President and CEO of Incyte,
explained, "The underlying demand for Jakafi was strong in the second quarter,
leading to our decision to increase guidance for 2013." The Full Research
Report on Incyte Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-14/INCY]

Santarus, Inc. Research Report

On August 6, 2013, Santarus, Inc. (Santarus) released its Q2 2013 financial
results. Total revenues were up 89.4% YoY to $89.4 million, while income from
operations increased 393.1% YoY to $18.7 million. Net income was up 2,032.7%
YoY to $73.5 million, while diluted EPS grew 1,780% YoY to $0.94, in Q2 2013.
For full-year 2013, Santarus expects GAAP net income to be between $129
million and $132 million; non-GAAP adjusted earnings to be between $97 million
and $101 million; and non-GAAP adjusted diluted EPS to be between $1.21 and
$1.26. The Full Research Report on Santarus, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.InvestorsReports.com/report/2013-08-14/SNTS]

ACADIA Pharmaceuticals Inc. Research Report

On August 6, 2013, ACADIA Pharmaceuticals Inc. (ACADIA) released its Q2 2013
financial results. Collaborative revenues were down 24.7% YoY to $0.5 million
during the quarter. Loss from operations was $9.2 million, compared to a loss
of $5.4 million in Q2 2012. Net loss stood at $9.1 million, or $0.11 per
diluted share, compared to a loss of $5.4 million, or $0.10 per diluted share,
in Q2 2012. Uli Hacksell, Ph.D., CEO of ACADIA, stated, "The second quarter of
2013 was a game-changing period for ACADIA, highlighted by establishing an
expedited path to an NDA filing for pimavanserin and by strengthening our
balance sheet through our public offering." Hacksell added, "This success sets
the stage for what we believe will be an exciting new phase for ACADIA focused
on building additional value in our pimavanserin franchise. We continue to
make solid progress towards completing the remaining activities in our
Parkinson's disease psychosis development program that are needed for our NDA
submission. Meanwhile, we are also finalizing preparations for our Phase II
feasibility study in Alzheimer's disease psychosis patients that we expect to
initiate this year. We plan to build on the positive momentum of the first
half of 2013 by continuing to advance our pipeline, led by pimavanserin, which
we believe positions ACADIA with multiple attractive product and commercial
opportunities." The Full Research Report on ACADIA Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-14/ACAD]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    making mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.